Nautilus Biotechnology Conference Summary Company Overview - **Company**: Nautilus Biotechnology (NasdaqGS: NAUT) - **Focus**: Revolutionizing biomedicine through proteomics, the study of proteins, to enhance drug development and precision medicine [1][40] Industry Insights - **Biotechnology Landscape**: The genomics revolution has been largely successful, but it has not significantly impacted drug development outside of oncology. Proteins, which are crucial for drug efficacy, have not been adequately analyzed, leading to high failure rates in drug development [2][3] - **Market Opportunity**: The proteomics market is projected to grow to $57 billion by 2030, with a CAGR of approximately 13%. This market is divided into biopharma (50%), academic/nonprofit research (30%), and applied applications [33][34] Core Challenges - **Current Proteomics Technologies**: Existing technologies yield low-quality results, leading to over 90% failure rates in new drug development programs. Current methods do not provide comprehensive data on proteins, which are essential for understanding diseases [3][10] - **Specific Disease Focus**: Alzheimer's disease, affecting 7 million Americans and costing over $1 trillion globally, exemplifies the need for better protein analysis tools. Despite decades of research, effective therapies remain elusive [3][4] Nautilus' Innovative Approach - **Disruptive Technology**: Nautilus is developing a new method called iterative mapping, which allows for high-quality, reproducible protein analysis across various sample types (blood, cells, tissues) [18][19] - **Platform Components**: The Nautilus platform includes the Voyager instrument, capable of analyzing up to 12 samples per day, and a cloud-based data analysis system. The expected cost of the Voyager is around $1 million [18][19][21] Product Development and Applications - **Current and Future Assays**: Nautilus has introduced a tau proteoform assay capable of measuring 768 different forms of tau, a key biomarker in Alzheimer's disease. This assay is currently in early access with plans for broader availability [25][26] - **Upcoming Targets**: The next focus will be on oncology targets, with a partnership with the Michael J. Fox Foundation to develop an assay for alpha-synuclein, a protein involved in Parkinson's disease [27][28] Financial Overview - **Cash Position**: As of the last quarter, Nautilus reported $156 million in cash, which is 45% of the funds raised during its IPO. The company expects this cash to last through 2027, allowing for continued development and market expansion [38][39] Strategic Vision - **Long-term Alignment**: The founders and board members hold significant shares in the company, indicating strong alignment with shareholder interests. The company aims to generate value through innovative products and strategic partnerships [40][41] Conclusion - **Market Potential**: Nautilus is positioned to unlock new clinical applications and drug opportunities through its innovative proteomics technology, with significant revenue growth expected as products become available [34][29]

Financial Data and Key Metrics Changes - Total operating expenses for Q4 2025 were $15.4 million, a decrease of 23% from the prior year period, and $66.8 million for the fiscal year 2025, a decrease of 18% year-over-year [20] - Research and development expenses were $41.1 million for fiscal year 2025, down from $50.5 million in fiscal year 2024, representing a decrease of 19% [20] - Cash burn in 2025 was $50.2 million, down from $57.8 million in 2024, reflecting lower headcount and development expenses [22] Business Line Data and Key Metrics Changes - The early access program for the tau proteoform assay is set to begin processing samples by the end of Q1 2026, with initial customer engagements primarily with academic key opinion leaders [23][24] - The company anticipates modest services revenue later in 2026, with a primary revenue ramp expected to begin in 2027 once instruments start shipping [23] Market Data and Key Metrics Changes - The company is expanding its proteoform capabilities into additional high-value disease targets, including a collaboration focused on alpha-synuclein proteoforms in Parkinson's disease, funded by a $1.6 million project [8][16] - The oncology market is identified as a compelling next opportunity, with plans to evaluate multiple oncology-focused candidate proteins [16] Company Strategy and Development Direction - Nautilus aims to transition from development to active customer engagement, with a focus on commercialization and external validation [5][9] - The company plans to introduce broad-scale capabilities into early access later in 2026 and expects to initiate commercial launch in late 2026 [26] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the technical foundation required to scale assays and broaden the target portfolio, reinforcing the belief in the transformative potential of their technology [18][26] - The company anticipates total operating expense growth of approximately 15%-20% in 2026, with cash burn expected to be in the range of $65 million-$70 million [22] Other Important Information - Nautilus unveiled the Voyager instrument at the US HUPO conference, receiving positive feedback from the research community [6][25] - The company has made significant progress in assay development and operational priorities, with a focus on delivering high-quality, commercial-ready products [15][18] Q&A Session Summary Question: What are the next milestones and metrics for improvement? - The completion of the final studies of the tau proteoform assay has been shared with early customers, who are excited about the quality of the assay [30] Question: Will there be any revenue from the commercial launch later this year? - The company anticipates a target of closer to half a million dollars for 2026, with the primary revenue ramp tied to instruments expected in 2027 [39] Question: How is the early access program progressing? - The early access program was launched earlier than planned due to positive early data, and the company is beginning to build its sales capacity [41]

Financial Data and Key Metrics Changes - Total operating expenses for Q4 2025 were $15.4 million, a decrease of 23% from the prior year period, and $66.8 million for the fiscal year 2025, a decrease of 18% year-over-year [18] - Research and development expenses were $41.1 million for fiscal year 2025, down from $50.5 million in fiscal year 2024, representing a decrease of 19% [18] - General and administrative expenses were $25.7 million for fiscal year 2025, compared to $31.0 million in fiscal year 2024, a decrease of 17% [19] - Cash burn in 2025 was $50.2 million, down from $57.8 million in 2024 [21] - The company ended the quarter with $156.1 million in cash equivalents and investments [20] Business Line Data and Key Metrics Changes - The early access program for the tau proteoform assay was launched in January 2026, with initial customer engagements primarily with academic key opinion leaders [22] - The company anticipates modest services revenue later in 2026, with a primary revenue ramp expected to begin in 2027 once instruments start shipping [22] Market Data and Key Metrics Changes - The company is expanding its proteoform capabilities into additional high-value disease targets, including a collaboration focused on alpha-synuclein proteoforms in Parkinson's disease [8][15] - The oncology market is identified as a compelling next opportunity, with plans to evaluate multiple oncology-focused candidate proteins [15] Company Strategy and Development Direction - Nautilus aims to transition from development to active customer engagement, focusing on commercialization and external validation [5][9] - The company plans to progress early access customers into tau services projects and expand early access to include a second proteoform assay focused on an oncology target [25] - The Voyager instrument is expected to be commercially launched in late 2026, with pre-orders opening and installations beginning in early 2027 [25] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the technical foundation required to scale assays and broaden the target portfolio, supporting future commercial deployment [17] - The company expects total operating expenses for 2026 to increase by approximately 15%-20% as it continues investing in platform development [21] - Management highlighted the importance of collaborations and external validation in demonstrating the platform's relevance and potential impact [12][16] Other Important Information - The company has received grant funding from the Michael J. Fox Foundation, expected to total approximately $1.2 million, to support the development of an alpha-synuclein proteoform assay [23] - Nautilus's proprietary Iterative Mapping methodology is designed to analyze single, intact protein molecules at scale, aiming to unlock new biological insights [4][5] Q&A Session Summary Question: What are the next milestones and metrics that will improve based on Q4 technical achievements? - Management highlighted the completion of the tau proteoform assay studies and shared data with early customers, who expressed excitement about the assay's quality [29] Question: Will there be any revenue from the commercial launch later this year? - Management anticipates modest services revenue later in 2026, with a target of around half a million dollars for 2026, while the main revenue ramp will occur in 2027 [39] Question: How is the early access program progressing and what feedback has been received? - Feedback from early customers has been positive, with excitement about the data quality and the ability to forge connections in research that were previously unattainable [42]

Core Insights - Nautilus Biotechnology, Inc. has launched the Voyager™ Platform, enabling the analysis of up to 10 billion intact proteins and proteoforms in a single run, enhancing next-generation proteomics across various research fields [3][4][5] Product Features - The Voyager Platform utilizes machine-learning powered analysis to identify and quantify intact protein molecules, featuring a user-friendly touchscreen interface and a benchtop design that does not require specialized lab facilities [4][5][13] - The platform's Iterative Mapping approach allows for rapid measurement of intact single-molecule proteins, accommodating a wide dynamic range and providing unique binding patterns for each molecule [5][13] Development and Testing - The Voyager Platform was successfully field-tested at the Buck Institute for Research on Aging, yielding novel insights into tau proteoform biology [4][10] - An Early Access Program was launched in January 2026, allowing researchers to utilize the platform's capabilities before its broader commercial availability expected in late 2026 [6][8] Applications and Impact - The initial offering of the Early Access Program includes the Nautilus Tau Proteoforms assay, which quantifies up to 768 full-length tau proteoform groups, critical for developing biomarkers and drug targets for neurodegenerative disorders like Alzheimer's disease [9][10] - The Voyager Platform aims to democratize access to proteomics, facilitating advancements in biomarker discovery, diagnostics, and therapeutic innovation [6][10] Future Presentations - Nautilus will present data on the Voyager Platform and its applications at the US HUPO 2026 conference, including sessions on tau proteoform analysis and large-scale proteoform detection capabilities [11][12]